e-learning
resources
London 2016
Sunday, 04.09.2016
IPF: from pathogenesis to treatment I
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis
Yong Chul Lee (Jeonju, Republic of Korea), Yong Chul Lee, So Ri Kim, Kyung Bae Lee, Hae Jin Park, Soon Ha Kim
Source:
International Congress 2016 – IPF: from pathogenesis to treatment I
Session:
IPF: from pathogenesis to treatment I
Session type:
Thematic Poster
Number:
783
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Yong Chul Lee (Jeonju, Republic of Korea), Yong Chul Lee, So Ri Kim, Kyung Bae Lee, Hae Jin Park, Soon Ha Kim. Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis. Eur Respir J 2016; 48: Suppl. 60, 783
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Related content which might interest you:
The immunomodulatory effect of protein S in pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Novel biomarkers in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Olodaterol attenuates bleomycin induced lung fibrosis in mice
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016
New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung
Source: International Congress 2015 – Inflammation and remodelling in lung disease
Year: 2015
Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Interaction between mitochondrial ROS and ER stress on PHMG-induced pulmonary fibrosis
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Infliximab, an anti-tumor necrosis factor-α attenuates bleomycin-induced pulmonary fibrosis in rats
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Role of midkine in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Does Rosemary leaves extract can attenuate lung injury in experimental pulmonary fibrosis in rats?
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Role of dendritic cells in pulmonary fibrosis in mice
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept